Telix Pharmaceuticals (TLPPF) Liabilities and Shareholders Equity (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $3.8 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 17.38% from the prior year.
• Liabilities and Shareholders Equity was $1.4 billion for Q2 2026 at Telix Pharmaceuticals, up from $1.2 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.4 billion in Q2 2026 and troughed at $264.3 million in Q4 2023.
• A 4-year average of $945.4 million and a median of $1.1 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 275.25% in 2024 and gained 17.38% in 2025, its largest moves.
• Over 4 years, Liabilities and Shareholders Equity stood at $264.3 million in 2023, then jumped by 275.25% to $991.7 million in 2024, then climbed by 17.38% to $1.2 billion in 2025, then increased by 17.0% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q2 2026), $1.2 billion (Q4 2025), and $991.7 million (Q4 2024), per Business Quant data.